Harness the Power.
Open the Possibilities.
Open the Possibilities.
Stabilizing the immune response. Enabling optimism for patients with inflammatory disease.
Learn how obefazimod is believed to work.
Our Scientific Journey
Novel MOA
Our researchers discovered a molecule with a novel mechanism of action (MOA) that harnesses the power of microRNA biology—specifically miR-124. This molecule, obefazimod, enhances the expression of miR-124, a naturally occurring microRNA that plays a critical role in regulating the immune response.
Therapeutic Innovation
We are on a scientific journey to explore how this new approach could be used to treat chronic inflammatory diseases. Our discovery has provided the opportunity to bring an innovative approach to treating inflammation.
Targeting Inflammatory Diseases
Our Science
Under dysregulated inflammatory conditions in preclinical studies, enhanced expression of miR-124 resulted in stabilized levels of multiple cytokines and chemokines, bringing them back to homeostatic levels. Simultaneously restoring multiple pathways to homeostatic levels may lower the potential for compensatory immune escape mechanisms, which may result in more durable, long-term efficacy.
Our Lead Drug Candidate
Obefazimod is an investigational, orally administered, once-daily small molecule in clinical development with a novel mechanism of action. It is the first and only molecule to enhance the expression of miR-124 in immune cells, a natural regulator of the inflammatory response.
Our Research
Our primary goal is to develop and commercialize obefazimod for the treatment of inflammatory diseases, starting with ulcerative colitis. In July 2025, we announced positive top-line results from the 8-week induction trials of obefazimod in UC, marking a key milestone in our clinical development program; 44-week maintenance data remain on track for Q2 2026.
Patient enrollment for ENHANCE-CD in Crohn’s disease was initiated in Q3 2024; 12-week induction data readout is anticipated in 2H 2026.
Our Pipeline
We are exploring the development of obefazimod for other inflammatory indications while simultaneously investigating follow-on compounds.
Abivax also owns a proprietary chemical library that we believe contains further untapped potential. We have launched a research program to turn that potential into a reality.